Press Release: [Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys™ gene therapy for Duchenne muscular dystrophy in non-ambulatory patients
Basel, 15 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new dosing restrictions, effective immediately, for ELEVIDYS™ (delandistrogene moxeparvovec), for non-ambulatory Duchenne muscular dystrophy (DMD) patients, irrespective of age, in both clinical and commercial settings. In the commercial setting, non-ambulatory patients should no longer receive Elevidys. In the clinical trial setting, enrolment…
Thu, 24 Apr 2025 01:30:00 GMT Group sales grew by 6%1 at constant exchange rates (CER; 7% in CHF), driven by high demand for newer medicines and diagnostic solutions.Pharmaceuticals Division sales rose by 8% (9% in CHF) on ...
Wed, 23 Apr 2025 22:00:00 GMT Roche CEO Thomas Schinecker ... More information: Media Release, 14 April 2025 Gazyva/GazyvaroLupus nephritis FDA accepts supplemental Biologics License Application for Gazyva/Gazyvaro for ...
Wed, 23 Apr 2025 18:00:00 GMT [Ad hoc announcement pursuant to Art. 53 LR] Roche continues good momentum into 2025 with 6% (CER) sales growth in the first quarter F. Hoffmann-La Roche Ltd Thu, Apr 24, 2025, 1:00 AM 20 min read ...
Wed, 29 Jan 2025 17:00:00 GMT If approved by shareholders, this would be the 38th consecutive dividend increase. Outlook for 2025 Roche (SIX: RO, ROG; OTCQX: RHHBY) expects an increase in Group sales in the mid single digit ...
Wed, 31 Jan 2024 22:00:00 GMT Roche CEO Thomas Schinecker ... and included in the official press programme More information: Media Release, 8 December 2023 InavolisibBreast cancer Inavolisib combination reduces the ...
